In addition, preclinical studies of FLT3-targeting chimeric antigen receptor T cell immunotherapy have demonstrated potent anti-leukemia activity in cell line (99, 100) and patient-derived xenograft models (Tasian, unpublished), further validating FLT3 as a robust therapeutic target in childhood AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.